Madrid. February 2006 – Cellerix, a biotechnology company, and the Spanish Innovation
Organisation (Empresa Nacional de Innovación, ENISA) signed a participative loan worth
900,000 euros, to be dedicated to Cellerix’s ongoing clinical trials. These funds, awarded by the
public company ENISA, a division of the Department of Industry, Tourism and Trade, help
Cellerix consolidate its clinical leadership in the use of adipose-derived stem cells. Cellerix is
conducting a Phase II trial treating anal fistulas. It is the only company in the world at this stage
of development using adult stem cells from adipose tissue as treatment. This product has
received orphan status designation by the EMEA for treating this indication in July ’05.
Cellerix, part of the Genetrix Group located in Madrid (Spain), is also developing a skin
regeneration product for treating Epidermolysis Bullosa, a rare and currently untreatable illness.
By using adult stem cells for therapy, Cellerix offers a real hope to patients suffering from these
illnesses to dramatically improve their quality of life, for which there are no satisfactory treatment
These types of loans awarded by ENISA allow the Department of Industry, Tourism and Trade
to offer invaluable, providing support to companies like Cellerix, by offering these loans at highly
discounted interest rates.
Cellerix is a biotechnology company belonging to the Genetrix Group, which actively develops
and produces innovative medicines based on the use of stem cells of adult origin. The company
is engaged in clinical Phase II trials for the treatment of complex perianal fistulas.
Operational since 2001, Cellerix is a clinically-focused cell therapy company. The company has
a developing product pipeline, targeting niche indications such as anal fistulas and skin
regeneration for Epidermolysis Bullosa.